Download MendeleyDiscovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.
Sharif, E.U., Kalisiak, J., Lawson, K.V., Miles, D.H., Newcomb, E., Lindsey, E.A., Rosen, B.R., Debien, L.P.P., Chen, A., Zhao, X., Young, S.W., Walker, N.P., Strater, N., Scaletti, E.R., Jin, L., Xu, G., Leleti, M.R., Powers, J.P.(2021) J Med Chem 64: 845-860
- PubMed: 33399453
- DOI: https://doi.org/10.1021/acs.jmedchem.0c01835
- Primary Citation of Related Structures:
6YE1, 6YE2 - PubMed Abstract:
Solid tumors are often associated with high levels of extracellular ATP. Ectonucleotidases catalyze the sequential hydrolysis of ATP to adenosine, which potently suppresses T-cell and NK-cell functions via the adenosine receptors (A 2a and A 2b ). The ectonucleotidase CD73 catalyzes the conversion of AMP to adenosine. Thus, increased CD73 enzymatic activity in the tumor microenvironment is a potential mechanism for tumor immune evasion and has been associated with poor prognosis in the clinic. CD73 inhibition is anticipated to restore immune function by skirting this major mechanism of adenosine generation. We have developed a series of potent and selective methylenephosphonic acid CD73 inhibitors via a structure-based design. Key binding interactions of the known inhibitor adenosine-5'-(α,β-methylene)diphosphate (AMPCP) with hCD73 provided the foundation for our early designs. The structure-activity relationship study guided by this structure-based design led to the discovery of 4a , which exhibits excellent potency against CD73, exquisite selectivity against related ectonucleotidases, and a favorable pharmacokinetic profile.
Organizational Affiliation:
Arcus Biosciences, Inc., 3928 Point Eden Way, Hayward, California 94545, United States.
